Effect of isradipine on in-vivo platelet function

Thrombosis Research

Volumn 86, Issue 5, 1997, Pages 363-371

  O'Grady, John ^a   Kritz, Harald ^a   Schmid, Peter ^b   Pirich, Christian ^c   Sinzinger, Helmut ^a  

^a Wilhelm Auerswald Atherosclerosis Research Group   (Austria)

^b Cardiovasc Rehab Ctr Bad S   (Austria)

^c Wilhelm Auerswald Atherosclerosis R ^*

Author keywords

Atherosclerosis; Hemostasis; Hypertension; In vivo; Isradipine; Platelet function

Indexed keywords

8 QUINOLINOL INDIUM IN 111; CALCIUM CHANNEL BLOCKING AGENT; ISRADIPINE;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION; THROMBOCYTE LIFESPAN;

ADULT; AGED; ARTERIOSCLEROSIS; BLOOD PLATELETS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; CELL SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; ISRADIPINE; MALE; MIDDLE AGED;

EID: 0030739224     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(97)00081-9     Document Type: Article

References (37)

1. ROSS, R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801-809, 1993.
2. FLECKENSTEIN, A., FREY, M., ZORN, J., FLECKENSTEIN, B. and GRÜN, G. The role of calcium in the pathogenesis of experimental arteriosclerosis. Trends Pharmacol Sci 8, 496-501, 1987.
3. GLEASON, M.M., MEDOW, M.S. and TULENKO, T.N. Excess cholesterol alters calcium flux and membrane fluidity in cultured arterial smooth muscle cells. Circulation 80, 63, 1989.
4. RUBANYI, G.M. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 22(Suppl 4), 1-14, 1994.
5. 2+ channel blockers. Atherosclerosis 88, 109-132, 1991.
6. DOYLE, A.E. Calcium antagonists. In: Handbook of Hypertension. W.H. Birkenhäger, J.L. Reidl, A.E. Doyle (eds.), pp. 424-428, Elsevier Science Publishers, Amsterdam (1988).
7. PARMLEY, W.W. Efficacy and safety of calcium channel blockers in hypertensive patients with concomitant left ventricular dysfunction. Clin Cardiol 15, 235-242, 1992.
8. HOLZGREVE, H. and BÜRKLE, B. Antiatherosclerotic effects of calcium antagonists. J Hypertens 11(Suppl), S55-59, 1993.
9. WEINSTEIN, D.B. and HEIDER, J.G. Antiatherogenic properties of calcium antagonists. Am J Cardiol 59(Suppl), B161-172, 1987.
10. LESLIE, J.B. Haemodynamics and tissue specificity with isradipine. Acta Anaesthesiol Scand Suppl 99, 33-37, 1993.
11. WEISS, K., FITSCHA, P., O'GRADY, J. and SINZINGER, H. Isradipine: a potent calcium blocker antagonist, with beneficial effects on the platelet function and vascular prostacyclin production. Thromb Res 54, 311-317, 1989.
12. 125I-LDL entry in hypercholesterinemic rabbits. J Cardiovasc Pharmacol 17, 546-550, 1991.
13. DALE, J., LANDMARK, K.H. and MYHRE, E. The effects of nifedipine, a calcium antagonist, on platelet function. Am Heart J 92, 103-105, 1983.
14. FITSCHA, P., VIRGOLINI, I., RAUSCHA, F. and SINZINGER, H. Effects of isradipine on platelet function in hypertension at rest and during exercise. Am J Hypertens 4, S178-180, 1991.
15. HONDA, I., MANABE, R. and MINATO, M. Effects of intravenous administration of a calcium antagonist on prostaglandins and thromboxane in plasma and urine in humans. Prostaglandins Leukot Essent Fatty Acids 23, 289-302, 1986.
16. SINZINGER, H., VIRGOLINI, I., RAUSCHA, F., FITSCHA, P. and O'Grady, J. Isradipine improves platelet function in hypertensives. Eur J Clin Pharmacol 42, 43-46, 1992.
17. 2 level and platelet aggregation in hypertensive patients. Drug Res 36, 1787-1789, 1986.
18. 111In-labeled platelets: a combined clinical and theoretical study In: Nuclear medicine and biology C. Raynaud (ed.), pp. 887-890, Pergamon, Paris (1982).
19. 111Indium. Arch Psychiatr Nervenkr 231, 449-457, 1982.
20. THAKUR, M.L., WELCH, M.J., JOIST, J.H. and COLEMAN, R.E. Indium-111-labeled platelets: studies on preparation and evaluation of in-vitro and in-vivo functions. Thromb Res 9, 345-357, 1976.
21. SINZINGER, H., KOLBE, H., STROBL-JÄGER, E. and HÖFER, R. A simple and safe technique for sterile autologous platelet labeling using "Monovette" vials. Eur J Nucl Med 9, 320-322, 1984.
22. MURPHY, E.A. and FRANCIS, M.E. The estimation of blood platelet survival. II. The multiple hit model. Thrombos Diathes Haemorrh 25, 53-80, 1971.
23. ISH. Panel of diagnostic application of radioisotopes in humans Reviewed methods for radioisotope platelet survival studies. Blood 50, 137-144, 1987.
24. SINZINGER, H. and FITSCHA, P. Epoprostenol and platelet deposition in atherosclerosis. Lancet i, 905-906, 1984.
25. JACKSON, C.L., BUSH, R.C. and BOWYER, D.E. Mechanism of antiatherogenic action of calcium antagonists. Atherosclerosis 80, 17-26, 1989.
26. VAN ZWIETEN, P.A., and PFAFFENDORF, M. Similarities and differences between calcium antagonists: pharmacological aspects. J Hypertens 11(Suppl), S3-11, 1993
27. 2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta. The effect of calcium antagonists. Atherosclerosis 72, 245-248, 1988.
28. SINZINGER, H., VIRGOLINI, I., O'GRADY, J., KEILER, A., LUPATTELLI, G., ANGELBERGER ,P. and MOLINARI, E. Aspirin abolishes the decreased low-density lipoprotein (LDL) entry into the rabbit arterial wall induced by the calcium channel blocker isradipine. Eicosanoids 5, 13-16, 1992.
29. 123I-low-density lipoproteins (LDL) in the diagnosis of human atherosclerotic lesions. Circulation 72, 300, 1985.
30. PRAMSOHLER, B., LUPATTELLI, G., SCHOLZ, H. and SINZINGER, H. Platelet scintigraphy and survival in juvenile stroke patients. Prog Clin Biol Res 355, 71-80, 1990.
31. SINZINGER, H. and VIRGOLINI, I. Nuclear medicine and atherosclerosis. Eur J Nucl Med 17, 160-178, 1990.
32. FETKOVSKA, N., FEDELESOVA, V., KOZLOVSKY, M. and DZRUIK, R. Platelet-activating effect of low-density lipoprotein and its reversal by isradipine. Am J Hypertens 4(Suppl), S175-177, 1991.
33. DING, Y.A., HAN, C.L., CHOU, T.Z., LAI, W.Y. and SHIAO, M.F. Effects of the calcium antagonist isradipine in 24-hour ambulatory blood pressure, platelet aggregation and neutrophile oxygen-free radicals in hypertension. J Cardiovasc Pharmacol 19(Suppl 3), S32-37, 1992.
34. RIEZBOS, J., VLEEMING, W., BEEMS, R.B., AMSTERDAM VAN, J.G.C., MEJER, G.W., WILDT DE, D.J., PORSIUS, A.J. and WEMER, J. Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: I. Effect on progression of atherosclerosis and endothelial dysfunction. J Cardiovasc Pharmacol 23, 415-423, 1994.
35. BLACHE, D. and OJEDA, C. Comparative inhibitory effects of dihydropyridines on platelet aggregation, calcium uptake and cyclic AMP concentration. Pharmacology 45, 250-259, 1992.
36. 2) from endothelial cells. Wien Klin Wochenschr 103, 422-434, 1991.
37. HASSAL, D.G., OWEN, J.S. and BRUCKDORFER, K.R. The aggregation of isolated platelets in the presence of lipoproteins and prostacyclin. Biochem J 242, 559-564, 1987.